Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Kawasaki Disease, Secondary Immune Deficiency, And Other Applications), Mode of Delivery (Intravenous, Intramuscular, Subcutaneous), and Concentration (5%, 10% and Other Concentration): Opportunity Analysis and Industry Forecast, 2014-2022
Intravenous immunoglobulin (IVIG) is a blood/plasma product, which is prepared from the serum of multiple of donors, used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. IVIG is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.
The Malaysia IVIG market was valued at $12,277 thousand in 2015, and is projected to reach $18,649 thousand by 2022, registering a CAGR of 6.1% during the forecast period. This is attributed to increase in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others. Increase in geriatric population & number of hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) drive the growth of the market. However, stringent government regulations toward IVIG products, expensive therapy, and high risk of side effects associated with the use of IVIG are expected to hamper the market growth.
The report segments the Malaysia IVIG market based on application, product type, mode of delivery, and concentration by both- value and volume. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, Kawasaki disease, secondary immune deficiency disease, and others.
Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to the large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular. On the basis of concentration, it is categorized into 5%, 10%, and others. The intravenous mode of delivery segment held the largest revenue share in 2015, and is anticipated to continue this trend during the forecast period.
KEY PLAYERS PROFILED
By Application
The Malaysia IVIG market was valued at $12,277 thousand in 2015, and is projected to reach $18,649 thousand by 2022, registering a CAGR of 6.1% during the forecast period. This is attributed to increase in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others. Increase in geriatric population & number of hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) drive the growth of the market. However, stringent government regulations toward IVIG products, expensive therapy, and high risk of side effects associated with the use of IVIG are expected to hamper the market growth.
The report segments the Malaysia IVIG market based on application, product type, mode of delivery, and concentration by both- value and volume. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, Kawasaki disease, secondary immune deficiency disease, and others.
Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to the large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular. On the basis of concentration, it is categorized into 5%, 10%, and others. The intravenous mode of delivery segment held the largest revenue share in 2015, and is anticipated to continue this trend during the forecast period.
KEY PLAYERS PROFILED
- Grifols S.A.,
- Octapharma AG
- Green Cross Corporation
- Baxalta (Shire)
- Bio Products Laboratory Ltd.
- Biotest AG,
- CSL Behring
- Omrix Biopharmaceuticals Ltd.
- Bayer Healthcare
- Baxter International Inc.
- The study provides an in-depth analysis of the Malaysia IVIG market and the current trends and future estimations to elucidate the imminent investment pockets.
- The report presents quantitative analysis of the market from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on applications assists to understand the trends in the industry.
- Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Immunodeficiency Diseases
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain-Barr? Syndrome
- Kawasaki Disease
- Secondary Immune Deficiency
- Others
- IgG
- IgA
- IgM
- IgE
- IgD
- Intravenous
- Intramuscular
- Subcutaneous
- 5% Concentration
- 10% Concentration
- Other Concentration
- BDI Pharma, Inc.
- China Biologics Products, Inc.
- LFB Biotechnologies
- Hualan Biological Engineering Inc.
- Guizhou Taibang Biological Products Co., Ltd.
- Beijing Tiantan Biological Products Co., Ltd.
- Shanghai Raas Blood Products Co. Ltd.
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG
3.2.1. Patented products
3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS
3.5.1. Top factors impacting Malaysia IVIG market
3.5.2. Top investment pockets
3.6. PORTERS FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS
3.7.1. Primary activities
3.7.2. Support activities
3.8. PRODUCT SCENARIO IN IVIG MARKET
3.9. GOVERNMENT REGULATIONS AND REIMBURSEMENTS
3.10. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)
3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4
3.11. MARKET DYNAMICS
3.11.1. Drivers
3.11.1.1. Rise in number of immunodeficiency diseases
3.11.1.2. Increase in adoption of IVIG
3.11.1.3. Increase in number of people with bleeding disorders
3.11.1.4. Rise in aging population
3.11.2. Restraints
3.11.2.1. Stringent regulations
3.11.2.2. High cost of IVIG therapy
3.11.3. Opportunities
3.11.3.1. Untapped potential of Malaysia as an emerging economy
3.11.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4 MALAYSIA IVIG MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD)
4.3.1. Market size and forecast
4.4. IMMUNODEFICIENCY DISEASES (ID)
4.4.1. Market size and forecast
4.5. MYASTHENIA GRAVIS (MG)
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY (MMN)
4.6.1. Market size and forecast
4.7. PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES (IM)
4.8.1. Market size and forecast
4.9. SPECIFIC ANTIBODY DEFICIENCY (SAD)
4.9.1. Market size and forecast
4.10. GUILLAIN-BARR SYNDROME (GBS)
4.10.1. Market size and forecast
4.11. KAWASAKI DISEASE (KD)
4.11.1. Market size and forecast
4.12. SECONDARY IMMUNE DEFICIENCY (SID)
4.12.1. Market size and forecast
4.13. OTHERS
4.13.1. Market size and forecast
CHAPTER 5 MALAYSIA IVIG MARKET, BY PRODUCT
5.1. OVERVIEW
5.2. IGG
5.2.1. Key market trends
5.2.2. Clinical interpretations
5.3. IGA
5.3.1. Key market trends
5.3.2. Clinical interpretations
5.4. IGM
5.4.1. Key market trends
5.4.2. Clinical interpretations
5.5. IGE
5.5.1. Key market trends
5.5.2. Clinical interpretations
5.6. IGD
5.6.1. Key market trends
5.6.2. Clinical interpretations
CHAPTER 6 MALAYSIA IVIG MARKET, BY MODE OF DELIVERY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Market size and forecast
6.4. INTRAMUSCULAR MODE OF DELIVERY
6.4.1. Market size and forecast
CHAPTER 7 MALAYSIA IVIG MARKET, BY CONCENTRATION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. 5% CONCENTRATION
7.2.1. Market size and forecast
7.3. 10% CONCENTRATION
7.3.1. Market size and forecast
7.4. OTHER CONCENTRATIONS
7.4.1. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. BAXTER INTERNATIONAL INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BIOTEST AG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. CSL LTD.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. GREEN CROSS CORPORATION
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GRIFOLS S.A.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. JOHNSON & JOHNSON
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. KEDRION S.P.A.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. OCTAPHARMA AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. SHIRE PLC
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG
3.2.1. Patented products
3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS
3.5.1. Top factors impacting Malaysia IVIG market
3.5.2. Top investment pockets
3.6. PORTERS FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS
3.7.1. Primary activities
3.7.2. Support activities
3.8. PRODUCT SCENARIO IN IVIG MARKET
3.9. GOVERNMENT REGULATIONS AND REIMBURSEMENTS
3.10. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)
3.10.1. IgG1
3.10.2. IgG2
3.10.3. IgG3
3.10.4. IgG4
3.11. MARKET DYNAMICS
3.11.1. Drivers
3.11.1.1. Rise in number of immunodeficiency diseases
3.11.1.2. Increase in adoption of IVIG
3.11.1.3. Increase in number of people with bleeding disorders
3.11.1.4. Rise in aging population
3.11.2. Restraints
3.11.2.1. Stringent regulations
3.11.2.2. High cost of IVIG therapy
3.11.3. Opportunities
3.11.3.1. Untapped potential of Malaysia as an emerging economy
3.11.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4 MALAYSIA IVIG MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIPD)
4.3.1. Market size and forecast
4.4. IMMUNODEFICIENCY DISEASES (ID)
4.4.1. Market size and forecast
4.5. MYASTHENIA GRAVIS (MG)
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY (MMN)
4.6.1. Market size and forecast
4.7. PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA (PITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES (IM)
4.8.1. Market size and forecast
4.9. SPECIFIC ANTIBODY DEFICIENCY (SAD)
4.9.1. Market size and forecast
4.10. GUILLAIN-BARR SYNDROME (GBS)
4.10.1. Market size and forecast
4.11. KAWASAKI DISEASE (KD)
4.11.1. Market size and forecast
4.12. SECONDARY IMMUNE DEFICIENCY (SID)
4.12.1. Market size and forecast
4.13. OTHERS
4.13.1. Market size and forecast
CHAPTER 5 MALAYSIA IVIG MARKET, BY PRODUCT
5.1. OVERVIEW
5.2. IGG
5.2.1. Key market trends
5.2.2. Clinical interpretations
5.3. IGA
5.3.1. Key market trends
5.3.2. Clinical interpretations
5.4. IGM
5.4.1. Key market trends
5.4.2. Clinical interpretations
5.5. IGE
5.5.1. Key market trends
5.5.2. Clinical interpretations
5.6. IGD
5.6.1. Key market trends
5.6.2. Clinical interpretations
CHAPTER 6 MALAYSIA IVIG MARKET, BY MODE OF DELIVERY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Market size and forecast
6.4. INTRAMUSCULAR MODE OF DELIVERY
6.4.1. Market size and forecast
CHAPTER 7 MALAYSIA IVIG MARKET, BY CONCENTRATION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. 5% CONCENTRATION
7.2.1. Market size and forecast
7.3. 10% CONCENTRATION
7.3.1. Market size and forecast
7.4. OTHER CONCENTRATIONS
7.4.1. Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. BAXTER INTERNATIONAL INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BIOTEST AG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. CSL LTD.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. GREEN CROSS CORPORATION
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GRIFOLS S.A.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. JOHNSON & JOHNSON
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. KEDRION S.P.A.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. OCTAPHARMA AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. SHIRE PLC
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments
LIST OF TABLES
TABLE 1. IGG SUBCLASS
TABLE 2. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 3. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
TABLE 4. MALAYSIA IVIG MARKET, BY APPLICATION, 2014-2022 ($THOUSAND)
TABLE 5. MALAYSIA IVIG MARKET, BY APPLICATION, 2014-2022 (KILOGRAM)
TABLE 6. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 7. MALAYSIA IVIG MARKET FOR HYPOGAMMAGLOBULINEMIA APPLICATION, 2014-2022 ($THOUSAND AND KILOGRAM)
TABLE 8. MALAYSIA IVIG MARKET FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 9. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
TABLE 10. MALAYSIA IVIG MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 11. MALAYSIA IVIG MARKET FOR MYASTHENIA GRAVIS APPLICATION, 2014-2022 ($THOUSAND AND KILOGRAM)
TABLE 12. MALAYSIA IVIG MARKET FOR MULTIFOCAL MOTOR NEUROPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 13. MALAYSIA IVIG MARKET FOR PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 14. MALAYSIA IVIG MARKET FOR INFLAMMATORY MYOPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 15. MALAYSIA IVIG MARKET FOR SPECIFIC ANTIBODY DEFICIENCY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 16. MALAYSIA IVIG MARKET FOR GUILLAIN-BARR SYNDROME APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 17. MALAYSIA IVIG MARKET FOR KAWASAKI DISEASE APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 18. IVIG MARKET FOR SECONDARY IMMUNODEFICIENCY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 19. MALAYSIA IVIG MARKET FOR OTHER APPLICATIONS, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 20. MALAYSIA IVIG MARKET, BY MODE OF DELIVERY, 2014-2022 ($THOUSAND)
TABLE 21. MALAYSIA IVIG MARKET, BY MODE OF DELIVERY, 2014-2022 (KILOGRAM)
TABLE 22. MALAYSIA IVIG MARKET FOR INTRAVENOUS MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 23. MALAYSIA IVIG MARKET FOR SUBCUTANEOUS MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 24. MALAYSIA IVIG MARKET FOR INTRAMUSCULAR MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 25. MALAYSIA IVIG MARKET, BY CONCENTRATION, 2014-2022 ($THOUSAND)
TABLE 26. MALAYSIA IVIG MARKET, BY CONCENTRATION, 2014-2022 (KILOGRAM)
TABLE 27. MALAYSIA IVIG MARKET FOR 5% CONCENTRATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 28. MALAYSIA IVIG MARKET FOR 10% CONCENTRATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 29. MALAYSIA IVIG MARKET FOR OTHER CONCENTRATIONS, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 30. BAXTER: COMPANY SNAPSHOT
TABLE 31. BAXTER: OPERATING SEGMENTS
TABLE 32. BAXTER: PRODUCT PORTFOLIO
TABLE 33. BAYER: COMPANY SNAPSHOT
TABLE 34. BAYER: OPERATING SEGMENTS
TABLE 35. BAYER: PRODUCT PORTFOLIO
TABLE 36. BIOTEST: COMPANY SNAPSHOT
TABLE 37. BIOTEST: OPERATING SEGMENTS
TABLE 38. BIOTEST: PRODUCT PORTFOLIO
TABLE 39. CSL: COMPANY SNAPSHOT
TABLE 40. CSL: OPERATING SEGMENTS
TABLE 41. CSL: PRODUCT PORTFOLIO
TABLE 42. GREEN CROSS: COMPANY SNAPSHOT
TABLE 43. GREEN CROSS: OPERATING SEGMENTS
TABLE 44. GREEN CROSS: PRODUCT PORTFOLIO
TABLE 45. GRIFOLS: COMPANY SNAPSHOT
TABLE 46. GRIFOLS: OPERATING SEGMENTS
TABLE 47. GRIFOLS: PRODUCT PORTFOLIO
TABLE 48. J&J: COMPANY SNAPSHOT
TABLE 49. J&J: OPERATING SEGMENTS
TABLE 50. J&J: PRODUCT PORTFOLIO
TABLE 51. KEDRION: COMPANY SNAPSHOT
TABLE 52. KEDRION: OPERATING SEGMENTS
TABLE 53. KEDRION: PRODUCT PORTFOLIO
TABLE 54. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 55. OCTAPHARMA: PRODUCTION AREAS
TABLE 56. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 57. SHIRE: COMPANY SNAPSHOT
TABLE 58. SHIRE: PRODUCT PORTFOLIO
TABLE 1. IGG SUBCLASS
TABLE 2. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 3. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
TABLE 4. MALAYSIA IVIG MARKET, BY APPLICATION, 2014-2022 ($THOUSAND)
TABLE 5. MALAYSIA IVIG MARKET, BY APPLICATION, 2014-2022 (KILOGRAM)
TABLE 6. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 7. MALAYSIA IVIG MARKET FOR HYPOGAMMAGLOBULINEMIA APPLICATION, 2014-2022 ($THOUSAND AND KILOGRAM)
TABLE 8. MALAYSIA IVIG MARKET FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 9. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
TABLE 10. MALAYSIA IVIG MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 11. MALAYSIA IVIG MARKET FOR MYASTHENIA GRAVIS APPLICATION, 2014-2022 ($THOUSAND AND KILOGRAM)
TABLE 12. MALAYSIA IVIG MARKET FOR MULTIFOCAL MOTOR NEUROPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 13. MALAYSIA IVIG MARKET FOR PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 14. MALAYSIA IVIG MARKET FOR INFLAMMATORY MYOPATHY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 15. MALAYSIA IVIG MARKET FOR SPECIFIC ANTIBODY DEFICIENCY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 16. MALAYSIA IVIG MARKET FOR GUILLAIN-BARR SYNDROME APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 17. MALAYSIA IVIG MARKET FOR KAWASAKI DISEASE APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 18. IVIG MARKET FOR SECONDARY IMMUNODEFICIENCY APPLICATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 19. MALAYSIA IVIG MARKET FOR OTHER APPLICATIONS, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 20. MALAYSIA IVIG MARKET, BY MODE OF DELIVERY, 2014-2022 ($THOUSAND)
TABLE 21. MALAYSIA IVIG MARKET, BY MODE OF DELIVERY, 2014-2022 (KILOGRAM)
TABLE 22. MALAYSIA IVIG MARKET FOR INTRAVENOUS MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 23. MALAYSIA IVIG MARKET FOR SUBCUTANEOUS MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 24. MALAYSIA IVIG MARKET FOR INTRAMUSCULAR MODE OF DELIVERY, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 25. MALAYSIA IVIG MARKET, BY CONCENTRATION, 2014-2022 ($THOUSAND)
TABLE 26. MALAYSIA IVIG MARKET, BY CONCENTRATION, 2014-2022 (KILOGRAM)
TABLE 27. MALAYSIA IVIG MARKET FOR 5% CONCENTRATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 28. MALAYSIA IVIG MARKET FOR 10% CONCENTRATION, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 29. MALAYSIA IVIG MARKET FOR OTHER CONCENTRATIONS, 2014-2022 ($THOUSAND & KILOGRAM)
TABLE 30. BAXTER: COMPANY SNAPSHOT
TABLE 31. BAXTER: OPERATING SEGMENTS
TABLE 32. BAXTER: PRODUCT PORTFOLIO
TABLE 33. BAYER: COMPANY SNAPSHOT
TABLE 34. BAYER: OPERATING SEGMENTS
TABLE 35. BAYER: PRODUCT PORTFOLIO
TABLE 36. BIOTEST: COMPANY SNAPSHOT
TABLE 37. BIOTEST: OPERATING SEGMENTS
TABLE 38. BIOTEST: PRODUCT PORTFOLIO
TABLE 39. CSL: COMPANY SNAPSHOT
TABLE 40. CSL: OPERATING SEGMENTS
TABLE 41. CSL: PRODUCT PORTFOLIO
TABLE 42. GREEN CROSS: COMPANY SNAPSHOT
TABLE 43. GREEN CROSS: OPERATING SEGMENTS
TABLE 44. GREEN CROSS: PRODUCT PORTFOLIO
TABLE 45. GRIFOLS: COMPANY SNAPSHOT
TABLE 46. GRIFOLS: OPERATING SEGMENTS
TABLE 47. GRIFOLS: PRODUCT PORTFOLIO
TABLE 48. J&J: COMPANY SNAPSHOT
TABLE 49. J&J: OPERATING SEGMENTS
TABLE 50. J&J: PRODUCT PORTFOLIO
TABLE 51. KEDRION: COMPANY SNAPSHOT
TABLE 52. KEDRION: OPERATING SEGMENTS
TABLE 53. KEDRION: PRODUCT PORTFOLIO
TABLE 54. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 55. OCTAPHARMA: PRODUCTION AREAS
TABLE 56. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 57. SHIRE: COMPANY SNAPSHOT
TABLE 58. SHIRE: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. MARKET SEGMENTATION
FIGURE 2. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
FIGURE 3. TOP FACTORS IMPACTING MALAYSIA IVIG MARKET (2015-2021)
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. BARGAINING POWER OF BUYERS
FIGURE 6. BARGAINING POWER OF SUPPLIERS
FIGURE 7. THREAT OF NEW ENTRANTS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. COMPETITIVE RIVALRY
FIGURE 10. VALUE CHAIN ANALYSIS OF MALAYSIA IVIG MARKET
FIGURE 11. BAXTER: NET SALES, 2014-2016 ($MILLION)
FIGURE 12. BAXTER: REVENUE BY PRODUCT, 2016 (%)
FIGURE 13. BAXTER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 14. BAYER: NET SALES, 2014-2016 ($MILLION)
FIGURE 15. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 16. BIOTEST: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. BIOTEST: REVENUE BY SEGMENT, 2016 (%)
FIGURE 18. BIOTEST: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 19. CSL: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. CSL: REVENUE BY PRODUCT, 2016 (%)
FIGURE 21. CSL: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 22. GREEN CROSS: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. GREEN CROSS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 24. GREEN CROSS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 25. GRIFOLS: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. GRIFOLS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 27. GRIFOLS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 28. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 29. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 30. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 31. KEDRION: NET SALES, 2014-2016 ($MILLION)
FIGURE 32. OCTAPHARMA: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. SHIRE: NET SALES, 2014-2016 ($MILLION)
FIGURE 34. SHIRE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 1. MARKET SEGMENTATION
FIGURE 2. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
FIGURE 3. TOP FACTORS IMPACTING MALAYSIA IVIG MARKET (2015-2021)
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. BARGAINING POWER OF BUYERS
FIGURE 6. BARGAINING POWER OF SUPPLIERS
FIGURE 7. THREAT OF NEW ENTRANTS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. COMPETITIVE RIVALRY
FIGURE 10. VALUE CHAIN ANALYSIS OF MALAYSIA IVIG MARKET
FIGURE 11. BAXTER: NET SALES, 2014-2016 ($MILLION)
FIGURE 12. BAXTER: REVENUE BY PRODUCT, 2016 (%)
FIGURE 13. BAXTER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 14. BAYER: NET SALES, 2014-2016 ($MILLION)
FIGURE 15. BAYER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 16. BIOTEST: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. BIOTEST: REVENUE BY SEGMENT, 2016 (%)
FIGURE 18. BIOTEST: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 19. CSL: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. CSL: REVENUE BY PRODUCT, 2016 (%)
FIGURE 21. CSL: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 22. GREEN CROSS: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. GREEN CROSS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 24. GREEN CROSS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 25. GRIFOLS: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. GRIFOLS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 27. GRIFOLS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 28. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 29. J&J: REVENUE BY SEGMENT, 2016 (%)
FIGURE 30. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 31. KEDRION: NET SALES, 2014-2016 ($MILLION)
FIGURE 32. OCTAPHARMA: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. SHIRE: NET SALES, 2014-2016 ($MILLION)
FIGURE 34. SHIRE: REVENUE BY GEOGRAPHY, 2016 (%)
